全体要約
2023年の急性呼吸窮迫症候群（ARDS）治療市場は、369.5百万米ドルと評価され、2030年には461.1百万米ドルに達する見込みで、年平均成長率（CAGR）は3.2%です。
市場の成長は、製品の差別化、コスト削減、サプライチェーンの最適化が重要であり、企業は研究開発や戦略的パートナーシップに投資する必要があります。
急性呼吸窮迫症候群（ARDS）は、主に早産児に見られる肺サーファクタントの欠乏によって引き起こされます。治療法には、サーファクタント療法や呼吸補助が含まれ、これらは新生児が生まれた直後から始まります。市場は、病院薬局、小売薬局、オンライン薬局などのセグメントに分かれています。
関連する質問
369.5百万USD（2023年）
3.2%（2023年から2030年）
Gilead Sciences Inc., Terumo Corporation, Getinge Ab, Livanova Plc, Medtronic, Alung Technologies, Inc., Armstrong Medical, Besmed Health Business Corp., Dragerwerk Ag & Co. Kgaa, Eurosets, F. Hoffmann-la Roche Ltd., Fisher & Paykel Healthcare Limited, Fresenius Se & Co. Kgaa, Hamilton Medical, Nice Neotech Medical Systems Pvt.ltd., Nipro, Pfizer Inc., Resmed, Smiths Medical, Weinmann Emergency Medical Technology Gmbh+co. Kg
製品差別化, コスト削減, サプライチェーン最適化
概要
この研究報告書では、世界の急性肺損傷症候群（ARDS）治療市場の成長可能性が強調されています。急性肺損傷症候群（ARDS）治療は、将来の市場で安定した成長を示すと予測されています。しかし、製品の差別化、コスト削減、そしてサプライチェーンの最適化は、急性肺損傷症候群（ARDS）治療の広範な導入にとって重要な要素です。市場のプレーヤーは、研究開発に投資し、戦略的パートナーシップを構築し、急性肺損傷症候群（ARDS）治療市場が提供する膨大な機会を活かすために、進化する消費者の好みに沿った提供を行う必要があります。
呼吸窮迫症候群は、新生児の肺における肺サーファクタントの不足によって引き起こされ、特に37週未満で生まれた赤ちゃんに最も一般的です。リスクは早産の程度に応じて増加します。症状には、鳴き声のような呼吸、補助筋の使用、出生後すぐに現れる鼻の膨らみが含まれます。診断は臨床的です；出生前のリスクは胎児の肺の成熟度に関する検査で評価できます。治療はサーファクタント療法と支持療法です。RDSの治療は通常、新生児が生まれたときに始まりますが、時には分娩室で行われることがあります。RDSの治療には、サーファクタント補充療法、人工呼吸器や鼻持続陽圧呼吸(NCPAP)装置からの呼吸支援、またはその他の支持療法が含まれます。
2022年の世界の製薬市場は1475億米ドルであり、今後6年間で年平均成長率（CAGR）5%で成長する見込みです。製薬市場は、化学薬品と生物学的製剤を含みます。生物学的製剤は2022年に3810億米ドルに達すると予想されています。一方、化学薬品市場は、2018年の1005億米ドルから2022年の1094億米ドルに増加すると見込まれています。製薬市場の要因としては、ヘルスケアに対する需要の増加、技術革新、慢性疾患の増加、製薬製造セグメントの発展のための民間および政府機関からの資金提供の増加、薬剤の研究開発活動の増加があります。しかし、業界は厳しい規制、高い研究開発コスト、特許の期限切れといった課題にも直面しています。企業は、競争力を維持し、製品を必要とする患者に届けるために、常に革新し、これらの課題に適応する必要があります。さらに、COVID-19のパンデミックは、ワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに敏感かつ柔軟に対応する必要性をさらに強調しています。
主な特徴：
急性呼吸窮迫症候群（ARDS）治療市場に関する報告書は、さまざまな側面を反映し、業界への貴重な洞察を提供します。
市場規模と成長：この調査報告書は、急性呼吸促迫症候群（ARDS）治療市場の現在の規模と成長についての概要を提供します。歴史的データ、タイプ別の市場セグメンテーション（例：経口、静脈注射）、および地域別の内訳が含まれる場合があります。
市場の推進要因と課題：このレポートは、急性呼吸窮迫症候群（ARDS）治療市場の成長を促す要因を特定し分析することができます。例えば、政府の規制、環境問題、技術の進歩、消費者の嗜好の変化などです。また、この業界が直面している課題、例えばインフラの限界、レンジアナイティ（航続距離の不安）、高い初期コストなどを強調することもできます。
競争環境：この調査報告書は、急性呼吸窮迫症候群（ARDS）治療市場における競争環境の分析を提供します。主要プレイヤーのプロフィール、市場シェア、戦略、および製品提供が含まれています。また、新興プレイヤーとその市場に対する潜在的な影響も強調される可能性があります。
技術の発展：この調査報告書では、急性呼吸窮迫症候群（ARDS）治療業界における最新の技術の進展について詳しく探ることができます。これには、急性呼吸窮迫症候群（ARDS）治療技術の進歩、新規参入者、新たな投資、急性呼吸窮迫症候群（ARDS）治療を形作るその他の革新が含まれます。
下流のプロクンベントの嗜好：この報告書は、急性呼吸窮迫症候群（ARDS）治療市場における顧客のプロクンベント行動と採用傾向を明らかにすることができます。顧客の購買決定に影響を与える要因や、急性呼吸窮迫症候群（ARDS）治療製品に対する嗜好が含まれています。
政府の政策とインセンティブ：この研究報告書では、急性呼吸窮迫症候群（ARDS）治療市場に対する政府の政策とインセンティブの影響を分析しています。これには、規制の枠組み、補助金、税制優遇措置、急性呼吸窮迫症候群（ARDS）治療市場の促進を目的としたその他の措置の評価が含まれる可能性があります。また、これらの政策が市場成長を促進する上での効果も評価しています。
環境への影響と持続可能性：この研究報告書では、急性呼吸窮迫症候群（ARDS）治療市場の環境への影響と持続可能性の側面を評価しています。
市場予測と将来の見通し：実施された分析に基づき、研究報告書は急性呼吸窮迫症候群（ARDS）治療業界の市場予測と見通しを提供します。これには、市場規模、成長率、地域動向、技術の進展や政策の発展に関する予測が含まれます。
提言と機会：報告書は、業界関係者、政策立案者、投資家への提言で締めくくられています。急性呼吸窮迫症候群（ARDS）治療市場の成長と発展に寄与し、出現するトレンドを活かし、課題を克服するために市場関係者が活用できる潜在的な機会を強調しています。
市場セグメンテーション:
急性呼吸窮迫症候群（ARDS）治療市場は、タイプ別およびアプリケーション別に分かれています。2019年から2030年の期間において、セグメント間の成長は、価値の面でタイプ別およびアプリケーション別の消費価値に関する正確な計算と予測を提供します。
タイプ別セグメンテーション
口腔
静脈注射
筋肉内注射
アプリケーション別のセグメンテーション
病院薬局
小売薬局
オンライン薬局
この報告書では、市場を地域ごとに分割しています。
アメリカ大陸
アメリカ合衆国
カナダ
メキシコ
ブラジル
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要なエキスパートから得られた情報や、企業のカバレッジ、製品ポートフォリオ、市場浸透率を分析した結果に基づいて選定されています。
ギリアド・サイエンシズ社
テルモ株式会社
ゲティンゲ社
リバノバ株式会社
メドトロニック
アルングテクノロジーズ株式会社
アームストロングメディカル
ベスメッドヘルスビジネス株式会社
ドレーガーワーク社（Drägerwerk AG & Co. KGaA）
ユーロセット
F. ホフマン・ラ・ロシュ株式会社
フィッシャー＆ペイケル・ヘルスケア社
フレスenius SE & Co. KGaA
ハミルトンメディカル
ナイス・ネオテック・メディカル・システムズ・プライベート・リミテッド
ニプロ
ファイザー株式会社
レスメド
スミスメディカル
ヴァインマン緊急医療技術株式会社+コー･ケーg
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 調査範囲
1.1 市場イントロダクション
1.2 対象年
1.3 調査目的
1.4 市場調査手法
1.5 調査プロセスとデータソース
1.6 経済指標
1.7 通貨
1.8 市場予測における留意事項
2 エグゼクティブサマリー
2.1 世界市場概要
2.1.1 グローバルの急性呼吸窮迫症候群（ARDS）治療市場規模、（2019年～2030年）
2.1.2 急性呼吸窮迫症候群（ARDS）治療市場規模、CAGR（地域別）（2019年 vs 2023年 vs 2030年）
2.2 急性呼吸窮迫症候群（ARDS）治療セグメント、タイプ別
2.2.1 オーラル
2.2.2 静脈注射
2.2.3 筋肉内注射
2.3 急性呼吸窮迫症候群（ARDS）治療市場規模：タイプ別
2.3.1 急性呼吸窮迫症候群（ARDS）治療市場規模、CAGR（タイプ別）（2019年 vs 2023年 vs 2030年）
2.3.2 グローバルの急性呼吸窮迫症候群（ARDS）治療市場規模、市場シェア（タイプ別）（2019年～2024年）
2.4 急性呼吸窮迫症候群（ARDS）治療セグメント、用途別
2.4.1 病院薬局
2.4.2 小売薬局
2.4.3 オンラインファーマシー
2.5 急性呼吸窮迫症候群（ARDS）治療市場規模：用途別
2.5.1 急性呼吸窮迫症候群（ARDS）治療市場規模、CAGR（用途別）（2019年 vs 2023年 vs 2030年）
2.5.2 グローバルの急性呼吸窮迫症候群（ARDS）治療市場規模、市場シェア（用途別）（2019年～2024年）
3 急性呼吸窮迫症候群（ARDS）治療市場規模：プレイヤー別
3.1 急性呼吸窮迫症候群（ARDS）治療市場規模、市場シェア（プレイヤー別）
3.1.1 グローバルにおける急性呼吸窮迫症候群（ARDS）治療市場の収益規模、プレイヤー別（2019年～2024年）
3.1.2 グローバルにおける急性呼吸窮迫症候群（ARDS）治療市場の収益シェア、プレイヤー別（2019年～2024年）
3.2 グローバルの急性呼吸窮迫症候群（ARDS）治療市場キープレイヤー拠点および提供製品
3.3 市場集中度分析
3.3.1 競合情勢分析
3.3.2 集中度レシオ（CR3、CR5、CR10）（2022年～2024年）
3.4 新製品・潜在的参入
3.5 M&A、拡大
4 急性呼吸窮迫症候群（ARDS）治療、地域別
4.1 急性呼吸窮迫症候群（ARDS）治療市場規模（地域別）（2019年～2024年）
4.2 アメリカズにおける急性呼吸窮迫症候群（ARDS）治療市場規模成長（2019年〜2024年）
4.3 APACにおける急性呼吸窮迫症候群（ARDS）治療市場規模成長（2019年〜2024年）
4.4 ヨーロッパにおける急性呼吸窮迫症候群（ARDS）治療市場規模成長（2019年〜2024年）
4.5 中東・アフリカにおける急性呼吸窮迫症候群（ARDS）治療市場規模成長（2019年〜2024年）
5 アメリカズ
5.1 アメリカズにおける急性呼吸窮迫症候群（ARDS）治療市場規模、国別（2019年〜2024年）
5.2 アメリカズにおける急性呼吸窮迫症候群（ARDS）治療市場規模、タイプ別（2019年〜2024年）
5.3 アメリカズにおける急性呼吸窮迫症候群（ARDS）治療市場規模、用途別（2019年〜2024年）
5.4 米国
5.5 カナダ
5.6 メキシコ
5.7 ブラジル
6 APAC
6.1 APACにおける急性呼吸窮迫症候群（ARDS）治療市場規模、地域別（2019年〜2024年）
6.2 APACにおける急性呼吸窮迫症候群（ARDS）治療市場規模、タイプ別（2019年〜2024年）
6.3 APACにおける急性呼吸窮迫症候群（ARDS）治療市場規模、用途別（2019年〜2024年）
6.4 中国
6.5 日本
6.6 韓国
6.7 東南アジア
6.8 インド
6.9 オーストラリア
7 ヨーロッパ
7.1 ヨーロッパの急性呼吸窮迫症候群（ARDS）治療 国別（2019年～2024年）
7.2 ヨーロッパにおける急性呼吸窮迫症候群（ARDS）治療市場規模、タイプ別（2019年〜2024年）
7.3 ヨーロッパにおける急性呼吸窮迫症候群（ARDS）治療市場規模、用途別（2019年〜2024年）
7.4 ドイツ
7.5 フランス
7.6 英国
7.7 イタリア
7.8 ロシア
8 中東・アフリカ
8.1 中東・アフリカの急性呼吸窮迫症候群（ARDS）治療 地域別（2019年～2024年）
8.2 中東・アフリカにおける急性呼吸窮迫症候群（ARDS）治療市場規模、タイプ別（2019年〜2024年）
8.3 中東・アフリカにおける急性呼吸窮迫症候群（ARDS）治療市場規模、用途別（2019年〜2024年）
8.4 エジプト
8.5 南アフリカ
8.6 イスラエル
8.7 トルコ
8.8 GCC地域
9 市場ドライバー・課題・トレンド
9.1 市場ドライバー・成長機会
9.2 市場課題・リスク
9.3 業界トレンド
10 グローバルの急性呼吸窮迫症候群（ARDS）治療市場、市場予測
10.1 グローバルの急性呼吸窮迫症候群（ARDS）治療、市場予測（地域別）（2025年～2030年）
10.1.1 グローバルの急性呼吸窮迫症候群（ARDS）治療、市場予測（地域別）（2025年～2030年）
10.1.2 アメリカズの急性呼吸窮迫症候群（ARDS）治療、市場予測
10.1.3 APACの急性呼吸窮迫症候群（ARDS）治療、市場予測
10.1.4 ヨーロッパの急性呼吸窮迫症候群（ARDS）治療、市場予測
10.1.5 中東・アフリカの急性呼吸窮迫症候群（ARDS）治療、市場予測
10.2 アメリカズの急性呼吸窮迫症候群（ARDS）治療、市場予測（国別）（2025年～2030年）
10.3 APACの急性呼吸窮迫症候群（ARDS）治療、市場予測（地域別）（2025年～2030年）
10.4 ヨーロッパの急性呼吸窮迫症候群（ARDS）治療、市場予測（国別）（2025年～2030年）
10.5 中東・アフリカの急性呼吸窮迫症候群（ARDS）治療、市場予測（地域別）（2025年～2030年）
10.6 グローバルの急性呼吸窮迫症候群（ARDS）治療、市場予測（タイプ別）（2025年～2030年）
10.7 グローバルの急性呼吸窮迫症候群（ARDS）治療、市場予測（用途別）（2025年～2030年）
11 キープレイヤー分析
11.1 Gilead Sciences Inc
11.2 Terumo Corporation
11.2.1 Terumo Corporation：企業情報
11.2.2 Terumo Corporation：急性呼吸窮迫症候群（ARDS）治療分野の提供製品
11.2.3 Terumo Corporation：急性呼吸窮迫症候群（ARDS）治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.2.4 Terumo Corporation：主要事業概要
11.2.5 Terumo Corporation：直近の展開
11.3 Getinge Ab
11.3.1 Getinge Ab：企業情報
11.3.2 Getinge Ab：急性呼吸窮迫症候群（ARDS）治療分野の提供製品
11.3.3 Getinge Ab：急性呼吸窮迫症候群（ARDS）治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.3.4 Getinge Ab：主要事業概要
11.3.5 Getinge Ab：直近の展開
11.4 Livanova Plc
11.4.1 Livanova Plc：企業情報
11.4.2 Livanova Plc：急性呼吸窮迫症候群（ARDS）治療分野の提供製品
11.4.3 Livanova Plc：急性呼吸窮迫症候群（ARDS）治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.4.4 Livanova Plc：主要事業概要
11.4.5 Livanova Plc：直近の展開
11.5 Medtronic
11.5.1 Medtronic：企業情報
11.5.2 Medtronic：急性呼吸窮迫症候群（ARDS）治療分野の提供製品
11.5.3 Medtronic：急性呼吸窮迫症候群（ARDS）治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.5.4 Medtronic：主要事業概要
11.5.5 Medtronic：直近の展開
11.6 Alung Technologies, Inc
11.7 Armstrong Medical
11.7.1 Armstrong Medical：企業情報
11.7.2 Armstrong Medical：急性呼吸窮迫症候群（ARDS）治療分野の提供製品
11.7.3 Armstrong Medical：急性呼吸窮迫症候群（ARDS）治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.7.4 Armstrong Medical：主要事業概要
11.7.5 Armstrong Medical：直近の展開
11.8 Besmed Health Business Corp
11.9 Dragerwerk Ag & Co\. Kgaa
11.9.1 Dragerwerk Ag & Co\. Kgaa：企業情報
11.9.2 Dragerwerk Ag & Co\. Kgaa：急性呼吸窮迫症候群（ARDS）治療分野の提供製品
11.9.3 Dragerwerk Ag & Co\. Kgaa：急性呼吸窮迫症候群（ARDS）治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.9.4 Dragerwerk Ag & Co\. Kgaa：主要事業概要
11.9.5 Dragerwerk Ag & Co\. Kgaa：直近の展開
11.10 Eurosets
11.10.1 Eurosets：企業情報
11.10.2 Eurosets：急性呼吸窮迫症候群（ARDS）治療分野の提供製品
11.10.3 Eurosets：急性呼吸窮迫症候群（ARDS）治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.10.4 Eurosets：主要事業概要
11.10.5 Eurosets：直近の展開
11.11 F\. Hoffmann-la Roche Ltd
11.12 Fisher & Paykel Healthcare Limited
11.12.1 Fisher & Paykel Healthcare Limited：企業情報
11.12.2 Fisher & Paykel Healthcare Limited：急性呼吸窮迫症候群（ARDS）治療分野の提供製品
11.12.3 Fisher & Paykel Healthcare Limited：急性呼吸窮迫症候群（ARDS）治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.12.4 Fisher & Paykel Healthcare Limited：主要事業概要
11.12.5 Fisher & Paykel Healthcare Limited：直近の展開
11.13 Fresenius Se & Co\. Kgaa
11.13.1 Fresenius Se & Co\. Kgaa：企業情報
11.13.2 Fresenius Se & Co\. Kgaa：急性呼吸窮迫症候群（ARDS）治療分野の提供製品
11.13.3 Fresenius Se & Co\. Kgaa：急性呼吸窮迫症候群（ARDS）治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.13.4 Fresenius Se & Co\. Kgaa：主要事業概要
11.13.5 Fresenius Se & Co\. Kgaa：直近の展開
11.14 Hamilton Medical
11.14.1 Hamilton Medical：企業情報
11.14.2 Hamilton Medical：急性呼吸窮迫症候群（ARDS）治療分野の提供製品
11.14.3 Hamilton Medical：急性呼吸窮迫症候群（ARDS）治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.14.4 Hamilton Medical：主要事業概要
11.14.5 Hamilton Medical：直近の展開
11.15 Nice Neotech Medical Systems Pvt\.ltd
11.16 Nipro
11.16.1 Nipro：企業情報
11.16.2 Nipro：急性呼吸窮迫症候群（ARDS）治療分野の提供製品
11.16.3 Nipro：急性呼吸窮迫症候群（ARDS）治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.16.4 Nipro：主要事業概要
11.16.5 Nipro：直近の展開
11.17 Pfizer Inc
11.18 Resmed
11.18.1 Resmed：企業情報
11.18.2 Resmed：急性呼吸窮迫症候群（ARDS）治療分野の提供製品
11.18.3 Resmed：急性呼吸窮迫症候群（ARDS）治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.18.4 Resmed：主要事業概要
11.18.5 Resmed：直近の展開
11.19 Smiths Medical
11.19.1 Smiths Medical：企業情報
11.19.2 Smiths Medical：急性呼吸窮迫症候群（ARDS）治療分野の提供製品
11.19.3 Smiths Medical：急性呼吸窮迫症候群（ARDS）治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.19.4 Smiths Medical：主要事業概要
11.19.5 Smiths Medical：直近の展開
11.20 Weinmann Emergency Medical Technology Gmbh\+co\. Kg
11.20.1 Weinmann Emergency Medical Technology Gmbh\+co\. Kg：企業情報
11.20.2 Weinmann Emergency Medical Technology Gmbh\+co\. Kg：急性呼吸窮迫症候群（ARDS）治療分野の提供製品
11.20.3 Weinmann Emergency Medical Technology Gmbh\+co\. Kg：急性呼吸窮迫症候群（ARDS）治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.20.4 Weinmann Emergency Medical Technology Gmbh\+co\. Kg：主要事業概要
11.20.5 Weinmann Emergency Medical Technology Gmbh\+co\. Kg：直近の展開
12 調査の結果・結論
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
The research report highlights the growth potential of the global Acute Respiratory Distress Syndrome (ARDS) Treatment market. Acute Respiratory Distress Syndrome (ARDS) Treatment are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Acute Respiratory Distress Syndrome (ARDS) Treatment. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Acute Respiratory Distress Syndrome (ARDS) Treatment market.
Respiratory distress syndrome is caused by pulmonary surfactant deficiency in the lungs of neonates, most commonly in those born at < 37 weeks’ gestation. Risk increases with degree of prematurity. Symptoms and signs include grunting respirations, use of accessory muscles, and nasal flaring appearing soon after birth. Diagnosis is clinical; prenatal risk can be assessed with tests of fetal lung maturity. Treatment is surfactant therapy and supportive care. Treatment for RDS usually begins as soon as a newborn is born, sometimes in the delivery room. Treatments for RDS include surfactant replacement therapy, breathing support from a ventilator or nasal continuous positive airway pressure (NCPAP) machine, or other supportive treatments.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Acute Respiratory Distress Syndrome (ARDS) Treatment market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Acute Respiratory Distress Syndrome (ARDS) Treatment market. It may include historical data, market segmentation by Type (e.g., Oral, Intravenous Injection), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Acute Respiratory Distress Syndrome (ARDS) Treatment market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Acute Respiratory Distress Syndrome (ARDS) Treatment market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Acute Respiratory Distress Syndrome (ARDS) Treatment industry. This include advancements in Acute Respiratory Distress Syndrome (ARDS) Treatment technology, Acute Respiratory Distress Syndrome (ARDS) Treatment new entrants, Acute Respiratory Distress Syndrome (ARDS) Treatment new investment, and other innovations that are shaping the future of Acute Respiratory Distress Syndrome (ARDS) Treatment.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Acute Respiratory Distress Syndrome (ARDS) Treatment market. It includes factors influencing customer ' purchasing decisions, preferences for Acute Respiratory Distress Syndrome (ARDS) Treatment product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Acute Respiratory Distress Syndrome (ARDS) Treatment market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Acute Respiratory Distress Syndrome (ARDS) Treatment market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Acute Respiratory Distress Syndrome (ARDS) Treatment market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Acute Respiratory Distress Syndrome (ARDS) Treatment industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Acute Respiratory Distress Syndrome (ARDS) Treatment market.
Market Segmentation:
Acute Respiratory Distress Syndrome (ARDS) Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Oral
Intravenous Injection
Intramuscular Injection
Segmentation by application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Gilead Sciences Inc.
Terumo Corporation
Getinge Ab
Livanova Plc
Medtronic
Alung Technologies, Inc.
Armstrong Medical
Besmed Health Business Corp.
Dragerwerk Ag & Co. Kgaa
Eurosets
F. Hoffmann-la Roche Ltd.
Fisher & Paykel Healthcare Limited
Fresenius Se & Co. Kgaa
Hamilton Medical
Nice Neotech Medical Systems Pvt.ltd.
Nipro
Pfizer Inc.
Resmed
Smiths Medical
Weinmann Emergency Medical Technology Gmbh+co. Kg
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2019-2030
2.1.2 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Acute Respiratory Distress Syndrome (ARDS) Treatment Segment by Type
2.2.1 Oral
2.2.2 Intravenous Injection
2.2.3 Intramuscular Injection
2.3 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Type
2.3.1 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Type (2019-2024)
2.4 Acute Respiratory Distress Syndrome (ARDS) Treatment Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Online Pharmacy
2.5 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Application
2.5.1 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Application (2019-2024)
3 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Player
3.1 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Players
3.1.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue by Players (2019-2024)
3.1.2 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Acute Respiratory Distress Syndrome (ARDS) Treatment by Regions
4.1 Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Regions (2019-2024)
4.2 Americas Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth (2019-2024)
4.3 APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth (2019-2024)
4.4 Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth (2019-2024)
4.5 Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth (2019-2024)
5 Americas
5.1 Americas Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2019-2024)
5.2 Americas Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Type (2019-2024)
5.3 Americas Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Region (2019-2024)
6.2 APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Type (2019-2024)
6.3 APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Acute Respiratory Distress Syndrome (ARDS) Treatment by Country (2019-2024)
7.2 Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Type (2019-2024)
7.3 Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment by Region (2019-2024)
8.2 Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Type (2019-2024)
8.3 Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Forecast by Regions (2025-2030)
10.1.1 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Forecast by Regions (2025-2030)
10.1.2 Americas Acute Respiratory Distress Syndrome (ARDS) Treatment Forecast
10.1.3 APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Forecast
10.1.4 Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Forecast
10.1.5 Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Forecast
10.2 Americas Acute Respiratory Distress Syndrome (ARDS) Treatment Forecast by Country (2025-2030)
10.2.1 United States Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.2.2 Canada Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.2.3 Mexico Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.2.4 Brazil Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.3 APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Forecast by Region (2025-2030)
10.3.1 China Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.3.2 Japan Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.3.3 Korea Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.3.4 Southeast Asia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.3.5 India Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.3.6 Australia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.4 Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Forecast by Country (2025-2030)
10.4.1 Germany Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.4.2 France Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.4.3 UK Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.4.4 Italy Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.4.5 Russia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.5 Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Forecast by Region (2025-2030)
10.5.1 Egypt Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.5.2 South Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.5.3 Israel Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.5.4 Turkey Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.5.5 GCC Countries Acute Respiratory Distress Syndrome (ARDS) Treatment Market Forecast
10.6 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Forecast by Type (2025-2030)
10.7 Global Acute Respiratory Distress Syndrome (ARDS) Treatment Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Gilead Sciences Inc.
11.1.1 Gilead Sciences Inc. Company Information
11.1.2 Gilead Sciences Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.1.3 Gilead Sciences Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Gilead Sciences Inc. Main Business Overview
11.1.5 Gilead Sciences Inc. Latest Developments
11.2 Terumo Corporation
11.2.1 Terumo Corporation Company Information
11.2.2 Terumo Corporation Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.2.3 Terumo Corporation Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Terumo Corporation Main Business Overview
11.2.5 Terumo Corporation Latest Developments
11.3 Getinge Ab
11.3.1 Getinge Ab Company Information
11.3.2 Getinge Ab Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.3.3 Getinge Ab Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Getinge Ab Main Business Overview
11.3.5 Getinge Ab Latest Developments
11.4 Livanova Plc
11.4.1 Livanova Plc Company Information
11.4.2 Livanova Plc Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.4.3 Livanova Plc Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Livanova Plc Main Business Overview
11.4.5 Livanova Plc Latest Developments
11.5 Medtronic
11.5.1 Medtronic Company Information
11.5.2 Medtronic Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.5.3 Medtronic Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Medtronic Main Business Overview
11.5.5 Medtronic Latest Developments
11.6 Alung Technologies, Inc.
11.6.1 Alung Technologies, Inc. Company Information
11.6.2 Alung Technologies, Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.6.3 Alung Technologies, Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Alung Technologies, Inc. Main Business Overview
11.6.5 Alung Technologies, Inc. Latest Developments
11.7 Armstrong Medical
11.7.1 Armstrong Medical Company Information
11.7.2 Armstrong Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.7.3 Armstrong Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Armstrong Medical Main Business Overview
11.7.5 Armstrong Medical Latest Developments
11.8 Besmed Health Business Corp.
11.8.1 Besmed Health Business Corp. Company Information
11.8.2 Besmed Health Business Corp. Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.8.3 Besmed Health Business Corp. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Besmed Health Business Corp. Main Business Overview
11.8.5 Besmed Health Business Corp. Latest Developments
11.9 Dragerwerk Ag & Co. Kgaa
11.9.1 Dragerwerk Ag & Co. Kgaa Company Information
11.9.2 Dragerwerk Ag & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.9.3 Dragerwerk Ag & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Dragerwerk Ag & Co. Kgaa Main Business Overview
11.9.5 Dragerwerk Ag & Co. Kgaa Latest Developments
11.10 Eurosets
11.10.1 Eurosets Company Information
11.10.2 Eurosets Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.10.3 Eurosets Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Eurosets Main Business Overview
11.10.5 Eurosets Latest Developments
11.11 F. Hoffmann-la Roche Ltd.
11.11.1 F. Hoffmann-la Roche Ltd. Company Information
11.11.2 F. Hoffmann-la Roche Ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.11.3 F. Hoffmann-la Roche Ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 F. Hoffmann-la Roche Ltd. Main Business Overview
11.11.5 F. Hoffmann-la Roche Ltd. Latest Developments
11.12 Fisher & Paykel Healthcare Limited
11.12.1 Fisher & Paykel Healthcare Limited Company Information
11.12.2 Fisher & Paykel Healthcare Limited Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.12.3 Fisher & Paykel Healthcare Limited Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Fisher & Paykel Healthcare Limited Main Business Overview
11.12.5 Fisher & Paykel Healthcare Limited Latest Developments
11.13 Fresenius Se & Co. Kgaa
11.13.1 Fresenius Se & Co. Kgaa Company Information
11.13.2 Fresenius Se & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.13.3 Fresenius Se & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Fresenius Se & Co. Kgaa Main Business Overview
11.13.5 Fresenius Se & Co. Kgaa Latest Developments
11.14 Hamilton Medical
11.14.1 Hamilton Medical Company Information
11.14.2 Hamilton Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.14.3 Hamilton Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Hamilton Medical Main Business Overview
11.14.5 Hamilton Medical Latest Developments
11.15 Nice Neotech Medical Systems Pvt.ltd.
11.15.1 Nice Neotech Medical Systems Pvt.ltd. Company Information
11.15.2 Nice Neotech Medical Systems Pvt.ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.15.3 Nice Neotech Medical Systems Pvt.ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Nice Neotech Medical Systems Pvt.ltd. Main Business Overview
11.15.5 Nice Neotech Medical Systems Pvt.ltd. Latest Developments
11.16 Nipro
11.16.1 Nipro Company Information
11.16.2 Nipro Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.16.3 Nipro Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 Nipro Main Business Overview
11.16.5 Nipro Latest Developments
11.17 Pfizer Inc.
11.17.1 Pfizer Inc. Company Information
11.17.2 Pfizer Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.17.3 Pfizer Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Pfizer Inc. Main Business Overview
11.17.5 Pfizer Inc. Latest Developments
11.18 Resmed
11.18.1 Resmed Company Information
11.18.2 Resmed Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.18.3 Resmed Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Resmed Main Business Overview
11.18.5 Resmed Latest Developments
11.19 Smiths Medical
11.19.1 Smiths Medical Company Information
11.19.2 Smiths Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.19.3 Smiths Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.19.4 Smiths Medical Main Business Overview
11.19.5 Smiths Medical Latest Developments
11.20 Weinmann Emergency Medical Technology Gmbh+co. Kg
11.20.1 Weinmann Emergency Medical Technology Gmbh+co. Kg Company Information
11.20.2 Weinmann Emergency Medical Technology Gmbh+co. Kg Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered
11.20.3 Weinmann Emergency Medical Technology Gmbh+co. Kg Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.20.4 Weinmann Emergency Medical Technology Gmbh+co. Kg Main Business Overview
11.20.5 Weinmann Emergency Medical Technology Gmbh+co. Kg Latest Developments
12 Research Findings and Conclusion
List of Tables Table 1. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions) Table 2. Major Players of Oral Table 3. Major Players of Intravenous Injection Table 4. Major Players of Intramuscular Injection Table 5. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions) Table 6. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Type (2019-2024) & ($ Millions) Table 7. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Type (2019-2024) Table 8. Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions) Table 9. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Application (2019-2024) & ($ Millions) Table 10. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Application (2019-2024) Table 11. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue by Players (2019-2024) & ($ Millions) Table 12. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue Market Share by Player (2019-2024) Table 13. Acute Respiratory Distress Syndrome (ARDS) Treatment Key Players Head office and Products Offered Table 14. Acute Respiratory Distress Syndrome (ARDS) Treatment Concentration Ratio (CR3, CR5 and CR10) & (2022-2024) Table 15. New Products and Potential Entrants Table 16. Mergers & Acquisitions, Expansion Table 17. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Regions 2019-2024 & ($ Millions) Table 18. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Regions (2019-2024) Table 19. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue by Country/Region (2019-2024) & ($ millions) Table 20. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue Market Share by Country/Region (2019-2024) Table 21. Americas Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2019-2024) & ($ Millions) Table 22. Americas Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Country (2019-2024) Table 23. Americas Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Type (2019-2024) & ($ Millions) Table 24. Americas Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Type (2019-2024) Table 25. Americas Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Application (2019-2024) & ($ Millions) Table 26. Americas Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Application (2019-2024) Table 27. APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Region (2019-2024) & ($ Millions) Table 28. APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Region (2019-2024) Table 29. APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Type (2019-2024) & ($ Millions) Table 30. APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Type (2019-2024) Table 31. APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Application (2019-2024) & ($ Millions) Table 32. APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Application (2019-2024) Table 33. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Country (2019-2024) & ($ Millions) Table 34. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Country (2019-2024) Table 35. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Type (2019-2024) & ($ Millions) Table 36. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Type (2019-2024) Table 37. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Application (2019-2024) & ($ Millions) Table 38. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Application (2019-2024) Table 39. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Region (2019-2024) & ($ Millions) Table 40. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Region (2019-2024) Table 41. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Type (2019-2024) & ($ Millions) Table 42. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Type (2019-2024) Table 43. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size by Application (2019-2024) & ($ Millions) Table 44. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Application (2019-2024) Table 45. Key Market Drivers & Growth Opportunities of Acute Respiratory Distress Syndrome (ARDS) Treatment Table 46. Key Market Challenges & Risks of Acute Respiratory Distress Syndrome (ARDS) Treatment Table 47. Key Industry Trends of Acute Respiratory Distress Syndrome (ARDS) Treatment Table 48. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Forecast by Regions (2025-2030) & ($ Millions) Table 49. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share Forecast by Regions (2025-2030) Table 50. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Forecast by Type (2025-2030) & ($ Millions) Table 51. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Forecast by Application (2025-2030) & ($ Millions) Table 52. Gilead Sciences Inc. Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 53. Gilead Sciences Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 54. Gilead Sciences Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 55. Gilead Sciences Inc. Main Business Table 56. Gilead Sciences Inc. Latest Developments Table 57. Terumo Corporation Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 58. Terumo Corporation Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 59. Terumo Corporation Main Business Table 60. Terumo Corporation Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 61. Terumo Corporation Latest Developments Table 62. Getinge Ab Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 63. Getinge Ab Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 64. Getinge Ab Main Business Table 65. Getinge Ab Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 66. Getinge Ab Latest Developments Table 67. Livanova Plc Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 68. Livanova Plc Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 69. Livanova Plc Main Business Table 70. Livanova Plc Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 71. Livanova Plc Latest Developments Table 72. Medtronic Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 73. Medtronic Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 74. Medtronic Main Business Table 75. Medtronic Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 76. Medtronic Latest Developments Table 77. Alung Technologies, Inc. Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 78. Alung Technologies, Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 79. Alung Technologies, Inc. Main Business Table 80. Alung Technologies, Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 81. Alung Technologies, Inc. Latest Developments Table 82. Armstrong Medical Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 83. Armstrong Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 84. Armstrong Medical Main Business Table 85. Armstrong Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 86. Armstrong Medical Latest Developments Table 87. Besmed Health Business Corp. Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 88. Besmed Health Business Corp. Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 89. Besmed Health Business Corp. Main Business Table 90. Besmed Health Business Corp. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 91. Besmed Health Business Corp. Latest Developments Table 92. Dragerwerk Ag & Co. Kgaa Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 93. Dragerwerk Ag & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 94. Dragerwerk Ag & Co. Kgaa Main Business Table 95. Dragerwerk Ag & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 96. Dragerwerk Ag & Co. Kgaa Latest Developments Table 97. Eurosets Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 98. Eurosets Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 99. Eurosets Main Business Table 100. Eurosets Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 101. Eurosets Latest Developments Table 102. F. Hoffmann-la Roche Ltd. Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 103. F. Hoffmann-la Roche Ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 104. F. Hoffmann-la Roche Ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 105. F. Hoffmann-la Roche Ltd. Main Business Table 106. F. Hoffmann-la Roche Ltd. Latest Developments Table 107. Fisher & Paykel Healthcare Limited Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 108. Fisher & Paykel Healthcare Limited Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 109. Fisher & Paykel Healthcare Limited Main Business Table 110. Fisher & Paykel Healthcare Limited Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 111. Fisher & Paykel Healthcare Limited Latest Developments Table 112. Fresenius Se & Co. Kgaa Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 113. Fresenius Se & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 114. Fresenius Se & Co. Kgaa Main Business Table 115. Fresenius Se & Co. Kgaa Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 116. Fresenius Se & Co. Kgaa Latest Developments Table 117. Hamilton Medical Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 118. Hamilton Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 119. Hamilton Medical Main Business Table 120. Hamilton Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 121. Hamilton Medical Latest Developments Table 122. Nice Neotech Medical Systems Pvt.ltd. Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 123. Nice Neotech Medical Systems Pvt.ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 124. Nice Neotech Medical Systems Pvt.ltd. Main Business Table 125. Nice Neotech Medical Systems Pvt.ltd. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 126. Nice Neotech Medical Systems Pvt.ltd. Latest Developments Table 127. Nipro Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 128. Nipro Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 129. Nipro Main Business Table 130. Nipro Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 131. Nipro Latest Developments Table 132. Pfizer Inc. Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 133. Pfizer Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 134. Pfizer Inc. Main Business Table 135. Pfizer Inc. Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 136. Pfizer Inc. Latest Developments Table 137. Resmed Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 138. Resmed Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 139. Resmed Main Business Table 140. Resmed Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 141. Resmed Latest Developments Table 142. Smiths Medical Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 143. Smiths Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 144. Smiths Medical Main Business Table 145. Smiths Medical Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 146. Smiths Medical Latest Developments Table 147. Weinmann Emergency Medical Technology Gmbh+co. Kg Details, Company Type, Acute Respiratory Distress Syndrome (ARDS) Treatment Area Served and Its Competitors Table 148. Weinmann Emergency Medical Technology Gmbh+co. Kg Acute Respiratory Distress Syndrome (ARDS) Treatment Product Offered Table 149. Weinmann Emergency Medical Technology Gmbh+co. Kg Main Business Table 150. Weinmann Emergency Medical Technology Gmbh+co. Kg Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 151. Weinmann Emergency Medical Technology Gmbh+co. Kg Latest Developments List of Figures Figure 1. Acute Respiratory Distress Syndrome (ARDS) Treatment Report Years Considered Figure 2. Research Objectives Figure 3. Research Methodology Figure 4. Research Process and Data Source Figure 5. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth Rate 2019-2030 ($ Millions) Figure 6. Acute Respiratory Distress Syndrome (ARDS) Treatment Sales by Geographic Region (2019, 2023 & 2030) & ($ millions) Figure 7. Acute Respiratory Distress Syndrome (ARDS) Treatment Sales Market Share by Country/Region (2023) Figure 8. Acute Respiratory Distress Syndrome (ARDS) Treatment Sales Market Share by Country/Region (2019, 2023 & 2030) Figure 9. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Type in 2023 Figure 10. Acute Respiratory Distress Syndrome (ARDS) Treatment in Hospital Pharmacy Figure 11. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market: Hospital Pharmacy (2019-2024) & ($ Millions) Figure 12. Acute Respiratory Distress Syndrome (ARDS) Treatment in Retail Pharmacy Figure 13. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market: Retail Pharmacy (2019-2024) & ($ Millions) Figure 14. Acute Respiratory Distress Syndrome (ARDS) Treatment in Online Pharmacy Figure 15. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market: Online Pharmacy (2019-2024) & ($ Millions) Figure 16. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Application in 2023 Figure 17. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Revenue Market Share by Player in 2023 Figure 18. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Regions (2019-2024) Figure 19. Americas Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2019-2024 ($ Millions) Figure 20. APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2019-2024 ($ Millions) Figure 21. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2019-2024 ($ Millions) Figure 22. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2019-2024 ($ Millions) Figure 23. Americas Acute Respiratory Distress Syndrome (ARDS) Treatment Value Market Share by Country in 2023 Figure 24. United States Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 25. Canada Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 26. Mexico Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 27. Brazil Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 28. APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Region in 2023 Figure 29. APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Type in 2023 Figure 30. APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Application in 2023 Figure 31. China Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 32. Japan Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 33. Korea Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 34. Southeast Asia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 35. India Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 36. Australia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 37. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Country in 2023 Figure 38. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Type (2019-2024) Figure 39. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Application (2019-2024) Figure 40. Germany Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 41. France Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 42. UK Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 43. Italy Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 44. Russia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 45. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Region (2019-2024) Figure 46. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Type (2019-2024) Figure 47. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share by Application (2019-2024) Figure 48. Egypt Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 49. South Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 50. Israel Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 51. Turkey Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 52. GCC Country Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Growth 2019-2024 ($ Millions) Figure 53. Americas Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 54. APAC Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 55. Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 56. Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 57. United States Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 58. Canada Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 59. Mexico Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 60. Brazil Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 61. China Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 62. Japan Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 63. Korea Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 64. Southeast Asia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 65. India Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 66. Australia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 67. Germany Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 68. France Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 69. UK Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 70. Italy Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 71. Russia Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 72. Spain Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 73. Egypt Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 74. South Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 75. Israel Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 76. Turkey Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 77. GCC Countries Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size 2025-2030 ($ Millions) Figure 78. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share Forecast by Type (2025-2030) Figure 79. Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market Size Market Share Forecast by Application (2025-2030)
